Alendronate Sodium Patent Expiration
Alendronate Sodium was first introduced by Organon Llc A Sub Of Organon And Co
Alendronate Sodium Patents
Given below is the list of patents protecting Alendronate Sodium, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Binosto | US9592195 | Stable effervescent bisphosphonate formulations with rapid solubilization characteristics | Dec 05, 2031 | Radius |
| Binosto | US7488496 | Effervescent compositions comprising bisphosphonates and methods related thereto |
Aug 11, 2023
(Expired) | Radius |
| Binosto | US7964212 | Effervescent compositions comprising phosphonates and methods related thereto |
Mar 06, 2023
(Expired) | Radius |
| Fosamax |
US5994329 (Pediatric) | Method for inhibiting bone resorption |
Jan 17, 2019
(Expired) | Merck |
| Fosamax |
US6015801 (Pediatric) | Method for inhibiting bone resorption |
Jan 17, 2019
(Expired) | Merck |
| Fosamax |
US6225294 (Pediatric) | Method for inhibiting bone resorption |
Jan 17, 2019
(Expired) | Merck |
| Fosamax | US5994329 | Method for inhibiting bone resorption |
Jul 17, 2018
(Expired) | Merck |
| Fosamax | US6015801 | Method for inhibiting bone resorption |
Jul 17, 2018
(Expired) | Merck |
| Fosamax | US6225294 | Method for inhibiting bone resorption |
Jul 17, 2018
(Expired) | Merck |
| Fosamax |
US5462932 (Pediatric) | Oral liquid alendronate formulations |
Nov 17, 2014
(Expired) | Merck |
| Fosamax | US5462932 | Oral liquid alendronate formulations |
May 17, 2014
(Expired) | Merck |
| Fosamax |
US5358941 (Pediatric) | Dry mix formulation for bisphosphonic acids with lactose |
Jun 02, 2013
(Expired) | Organon |
| Fosamax |
US5681590 (Pediatric) | Dry mix formulation for bisphosphonic acids |
Jun 02, 2013
(Expired) | Organon |
| Fosamax |
US6090410 (Pediatric) | Dry mix formulation for bisphosphonic acids |
Jun 02, 2013
(Expired) | Organon |
| Fosamax |
US6194004 (Pediatric) | Dry mix formulation for bisphosphonic acids |
Jun 02, 2013
(Expired) | Organon |
| Fosamax | US5358941 | Dry mix formulation for bisphosphonic acids with lactose |
Dec 02, 2012
(Expired) | Organon |
| Fosamax | US5681590 | Dry mix formulation for bisphosphonic acids |
Dec 02, 2012
(Expired) | Organon |
| Fosamax | US6090410 | Dry mix formulation for bisphosphonic acids |
Dec 02, 2012
(Expired) | Organon |
| Fosamax | US6194004 | Dry mix formulation for bisphosphonic acids |
Dec 02, 2012
(Expired) | Organon |
Alendronate Sodium's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Alendronate Sodium:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
| Title | Lead Sponsor | Collaborators | Status | Phases |
|---|---|---|---|---|
 | ||||
| A Phase II Trial of RAB001 (LLP2A-Alendronate) for Steroid-Induced Early-Stage Osteonecrosis of the Femoral Head | ZhongShan LaiBo RuiChen BioMedicine Co.,Ltd. | NA |
ACTIVE NOT RECRUITING
(Mar 1, 2026)
| PHASE2 |